Improving Therapeutic Outcomes in BPH Through Diagnosis, Treatment and Patient Compliance

American Journal of Medicine

Volumn 121, Issue 8 SUPPL.2, 2008, Pages

  DeCastro, Joel ^a   Stone, Brian ^a  

^a Columbia University ^*  (United States)

Author keywords

Adherence; Benign prostatic hyperplasia; Communication; Diagnosis; Treatment

Indexed keywords

ALFUZOSIN; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ARTICLE; CULTURAL COMPETENCE; CULTURAL FACTOR; DIZZINESS; EDUCATIONAL STATUS; ETHNICITY; GYNECOMASTIA; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HISPANIC; HUMAN; HYPOTENSION; INTERPERSONAL COMMUNICATION; LASER SURGERY; LOWER URINARY TRACT SYMPTOM; MINORITY GROUP; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RACE DIFFERENCE; SEXUAL DYSFUNCTION; SYNCOPE; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC ALPHA-ANTAGONISTS; COMMUNICATION BARRIERS; HUMANS; MALE; MINORITY GROUPS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 48149094578     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.05.024     Document Type: Article

References (51)

1. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481-487
2. Sarma A.V., Wei J.T., Jacobson D.J., et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology 61 (2003) 1086-1091
3. Kaplan S.A., Reis R.B., Staiman V.B., and Te A.E. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts?. Br J Urol 82 (1998) 804-807
4. Sidney S., Quesenberry Jr. C.P., Sadler M.C., Guess H.A., Lydick E.G., and Cattolica E.V. Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan. Am J Epidemiol 134 (1991) 825-839
5. Merrill R.M., Potosky A.L., and Feuer E.J. Changing trends in US prostate cancer incidence rates. J Natl Cancer Inst 88 (1996) 1683-1685
6. Xia Z., Roberts R.O., Schottenfeld D., Lieber M.M., and Jacobsen S.J. Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994. Urology 53 (1999) 1154-1159
7. Derbes V.D.P., Leche S.M., and Hooker C.W. The incidence of benign prostatic hypertrophy among the whites and Negroes in New Orleans. J Urol 38 (1937) 383-388
8. Guess H.A. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 14 (1992) 131-153
9. Jacobsen S.J., Girman C.J., Guess H.A., Oesterling J.E., and Lieber M.M. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 155 (1995) 477-481
10. Jacobsen S.J., Guess H.A., Panser L., et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med 2 (1993) 729-735
11. Meigs J.B., Mohr B., Barry M.J., Collins M.M., and McKinlay J.B. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54 (2001) 935-944
12. Platz E.A., Kawachi I., Rimm E.B., Willett W.C., and Giovannucci E. Race, ethnicity and benign prostatic hyperplasia in the Health Professionals Follow-up Study. J Urol 163 (2000) 490-495
13. Kaplan S.A., Goluboff E.T., Olsson C.A., Deverka P.A., and Chmiel J.J. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 45 (1995) 398-405
14. Martinez M., Maislos S., and Rayford W. How to engage the Latino or African American patient with benign prostatic hyperplasia: crossing socioeconomic and cultural barriers. Am J Med 121 (2008) S11-S17 [suppl]
15. Collins M.M., Barry M.J., Bin L., Roberts R.G., Oesterling J.E., and Fowler F.J. Diagnosis and treatment of benign prostatic hyperplasia: practice patterns of primary care physicians. J Gen Intern Med 12 (1997) 224-229
16. Monda J.M., and Oesterling J.E. Medical treatment of benign prostatic hyperplasia: 5α-reductase inhibitors and α-adrenergic antagonists. Mayo Clin Proc 68 (1993) 670-679
17. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
18. McConnell J.D., Barry M.J., and Bruskewitz R.C. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guidelines Quick Reference Guide for Clinicians (1994), Agency for Health Care Policy and Research, US Dept of Health and Human Services. February, Rockville, MD 1-17 AHCPR publication no. 94-0583
19. Plawker M.W., Fleisher J.M., Nitti V.W., and Macchia R.J. Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer. J Urol 155 (1996) 601-604
20. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group, Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335 (1996) 533-539
21. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group, McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
22. Collins M.F., Friedman R.H., Ash A., Hall R., and Moskowitz M.A. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med 11 (1996) 513-518
23. Partin A.W. Prostate cancer-educating ourselves and our nonurological colleagues. J Urol 155 (1996) 610-611
24. Roehrborn C.G., Boyle P., Gould A.L., and Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53 (1999) 581-589
25. Roehrborn C.G., Dolte K.S., Ross K.S., and Girman C.J. Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas. Urology 56 (2000) 9-18
26. Roehrborn C.G., Malice M., Cook T.J., and Girman C.J. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58 (2001) 210-216
27. Fitzpatrick J.M. The natural history of benign prostatic hyperplasia. BJU Int 97 suppl 2 (2006) 3-6 discussion 21-22
28. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. In: Smedley B.D., Stith A.Y., and Nelson A.R. (Eds) (2002), National Academies Press, Washington, DC
29. Lillie-Blanton M., Maddox T.M., Rushing O., and Mensah G.A. Disparities in cardiac care: rising to the challenge of Healthy People 2010. J Am Coll Cardiol 44 (2004) 503-508
30. Collins M.M., Meigs J.B., Barry M.J., Walker Corkery E., Giovannucci E., and Kawachi I. Prevalence and correlates of prostatitis in the Health Professionals Follow-up Study cohort. J Urol 167 (2002) 1363-1366
31. Lepor H. Medical therapy for benign prostatic hyperplasia. Urology 42 (1993) 483-501
32. Lepor H., Williford W.O., Barry M.J., Hoakenson C., Jones K., and Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 160 (1998) 1358-1367
33. Colon I., and Payne R. Benign prostatic hyperplasia and lower urinary tract symptoms in African Americans and Latinos: treatment in the context of common comorbidities. Am J Med 121 suppl (2008) S18-S26
34. Haltbakk J., Hanestad B.R., and Hunskaar S. How important are men's lower urinary tract symptoms (LUTS) and their impact on the quality of life (QOL)?. Qual Life Res 14 (2005) 1733-1741
35. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
36. Wills C.E., Holmes-Rovner M., Rovner D., et al. Treatment preference patterns during a videotape decision aid for benign prostatic hyperplasia (BPH). Patient Educ Couns 61 (2006) 16-22
37. Rovner D.R., Wills C.E., Bonham V., et al. Decision aids for benign prostatic hyperplasia: applicability across race and education. Med Decis Making 24 (2004) 359-366
38. Committee on Communication for Behavior Change in the 21st Century. Improving the Health of Diverse Populations. Speaking of Health: Assessing Health Communication Strategies for Diverse Populations (2002), The National Academies Press, Washington, DC
39. Verhamme K.M., Dieleman J.P., Bleumink G.S., Bosch J.L., Stricker B.H., and Sturkenboom M.C. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 44 (2003) 539-545
40. Speakman M.J. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what is the available evidence for rational management?. Eur Urol 39 suppl 3 (2001) 6-12
41. Cam K., Akman Y., Kayikci A., Senel F., and Erol A. Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms. Int J Urol 10 (2003) 582-586
42. Akduman B., and Crawford E.D. Terazosin, doxazosin, and prazosin: current clinical experience. Urology 58 suppl 1 (2001) 49-54
43. Kaplan S.A., and Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology 67 (2006) 225-231
44. Andriole G.L., and Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44 (2003) 82-88
45. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 97 suppl 2 (2006) 34-38
46. Weinrich S.P., Boyd M.D., Bradford D., Mossa M.S., and Weinrich M. Recruitment of African Americans into prostate cancer screening. Cancer Pract 6 (1998) 23-30
47. Elder J.P., Ayala G.X., Campbell N.R., Arredondo E.M., et al. Long-term effects of a communication intervention for Spanish-dominant Latinas. Am J Prev Med 31 (2006) 159-166
48. Zuvekas A., Nolan L., Tumaylle C., and Griffin L. Impact of community health workers on access, use of services, and patient knowledge and behavior. J Ambul Care Manage 22 (1999) 33-44
49. Gary T.L., Narayan K.M., Gregg E.W., Beckles G.L., and Saaddine J.B. Racial/ethnic differences in the healthcare experience (coverage, utilization, and satisfaction) of US adults with diabetes. Ethn Dis 13 (2003) 47-54
50. Perez-Stable E.J., and Salazar R. Issues in achieving compliance with antihypertensive treatment in the Latino population. Clin Cornerstone 6 (2004) 49-61 discussion 62-64
51. Weissman J.S., Betancourt J., Campbell E.G., et al. Resident physicians' preparedness to provide cross-cultural care. JAMA 294 (2005) 1058-1067